Alexandria Real Estate Equities, Inc. Announces Foundational Milestone in Mission-Critical Partnership with the Foundation for the National Institutes of Health to Advance Precision Medicine for Depression

PASADENA, Calif, July 29, 2026 — Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation clusters, today announced with the Foundation for the National Institutes of Health (FNIH) that the Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative has successfully completed its critical design phase, marking a foundational milestone toward a first-of-its-kind clinical study designed to redefine how major depressive disorder is diagnosed and treated through precision medicine. Launched with Alexandria's vision and first funding, and founded on its strategic partnership with the FNIH, MAP-D seeks to identify and validate biological signatures of depression that can enable more personalized treatment approaches, accelerate the development of more effective therapies and ultimately improve outcomes for millions of patients.

"Major depressive disorder affects more than 21 million adults in the United States each year, nearly one-third of whom suffer from treatment-resistant depression," said Lynne Zydowsky, PhD, chief of science at Alexandria Real Estate Equities, Inc./Alexandria Venture Investments. "For too long, depression has been diagnosed primarily through symptoms and treated as a single disease, despite the biological differences that exist from one patient to another and the frequent overlap with related conditions such as PTSD. We are proud to partner with the FNIH to advance a transformative precision medicine framework that has the potential to fundamentally improve how depression is understood, diagnosed and treated."

Alexandria is the FNIH's founding strategic partner, providing the initial catalytic funding and securing the strategic cross-sector support required to establish the public-private partnership and launch the MAP-D initiative. In 2025, the FNIH honored Alexandria with the prestigious Charles A. Sanders, MD, Partnership Award in recognition of the company's extraordinary contributions to accelerating biomedical innovation, exemplified by Alexandria's leadership in advancing this highly consequential initiative.

Completion of the MAP-D design phase establishes the scientific framework for a long-term clinical study that aims to generate one of the most comprehensive depression research datasets ever assembled. As announced today by the FNIH, the initiative is advancing toward a research effort expected to exceed $70 million, beginning with a $22 million, three-year pilot phase. The study will leverage advanced artificial intelligence models to identify relationships between biological markers and patient outcomes. Ultimately, MAP-D seeks to establish biologically informed subtypes of depression, enable more precise treatment selection and accelerate the development of new therapies. Among its critical objectives, the public-private partnership will strive to make its data broadly accessible to qualified researchers, foster transparency, accelerate scientific discovery and extend the benefits of its precision medicine framework to other serious mental illnesses. To learn more about the MAP-D initiative and its partners, please visit fnih.org/our-programs/multi-modal-assessment-phenotyping-depression.

About Alexandria Real Estate Equities, Inc. Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. For more information, please visit www.are.com.